"""Scientific/medical professionals, regulatory agencies, investors, etc are likely to approach and accept epigenetic therapies, including BET inhibition, with both more caution and more skepticism as compared to more "conventional" therapies"""

That can cut both ways. If A is successful in Phase 3, and people don't really understand it, then they won't understand its limitations, either. That can lead to the kind of blue-sky thinking that's going on now with Vascepa.